Results 51 to 60 of about 2,071 (176)

Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

Dermatology Reports
According to the Italian Medicines Agency (AIFA) guidelines, patients with moderate-to-severe psoriasis can access biological therapies in case of treatment failure or contraindication to at least one conventional systemic treatment. However, no studies
Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando   +8 more
doaj   +1 more source

Dissecting Cellulitis and Hidradenitis Suppurativa: Two Diseases or One Follicular‐Occlusion Spectrum?

International Journal of Dermatology, EarlyView.
Graphical abstract summarizing evidence that dissecting cellulitis of the scalp (DC) and hidradenitis suppurativa (HS) may represent site‐modified expressions of a shared follicular‐occlusion pathway, highlighting convergent clinical, histopathologic, and therapeutic features, the diagnostic‐context paradox, and the need for paired molecular studies ...
Giuseppe Gallo, Federica Repetto, Orsola Crespi, Isotta Giunipero di Corteranzo, Luca Mastorino, Pietro Quaglino, Simone Ribero   +6 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos, Vincent Piguet, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Victoria Shodimu, Abby Paine, Brian Kirby, Haley B. Naik   +9 more
wiley   +1 more source

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis

Rheumatology and Therapy
Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis (r-axSpA; i.e.
Walter P. Maksymowych, Howard Thom, Michael F. Mørup, Vanessa Taieb, Damon Willems, Nikos Lyris, Karl Gaffney   +6 more
doaj   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Dermatology and Therapy
Introduction Patient demographics, disease characteristics, and treatment history can impact the efficacy of biologic treatments in patients with psoriasis. Understanding the efficacy of biologics, such as bimekizumab, across diverse patient subgroups is
Bruce Strober, Wolf-Henning Boehncke, James G. Krueger, Nina Magnolo, Ronald Vender, Richard B. Warren, José Manuel López Pinto, Sarah Kavanagh, Bengt Hoepken, Paolo Gisondi   +9 more
doaj   +1 more source

Therapeutic Inertia in Hidradenitis Suppurativa: Could Defensive Medicine Play a Role?

JEADV Clinical Practice, EarlyView.
Anju George, Alejandro Molina‐Leyva
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis [PDF]

, 2023
OBJECTIVES: To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of interleukin‑17F and 17A, with biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in non-radiographic axial ...
Willems, Damon, Taieb, Vanessa, Orme, Michelle, Pritchett, David, Machado, Pedro M, Deodhar, Atul, Gensler, Lianne S, Mørup, Michael   +7 more
core